SCHEMBL4958940

SCHEMBL4958940

CSc1ccc(-c2ncccc2C(=O)c2ccccn2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 3/20 0.45
GRM4 Q14833 1/20 0.45
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 2/20 0.42
RORB Q92753 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
LMNA P02545 2/20 0.40
NAPRT Q6XQN6 1/20 0.40
P4HTM Q9NXG6 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CTNNB1 P35222 1/20 0.40
WNT3A P56704 1/20 0.40
KDM4E B2RXH2 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
CTSK P43235 1/20 0.38
GAA P10253 1/20 0.38
BDKRB1 P46663 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4957779 0.80 PTGS2 (0.57) RAB9ASMN1; SMN2NPC1KMT2AALDH1A1
SCHEMBL4958812 0.77 ABL1 (0.40) RAB9ASMN1; SMN2NPC1KMT2ARORB
SCHEMBL11606099 0.76 RAB9A (0.52) RAB9ASMN1; SMN2NPC1GRM4KMT2A
SCHEMBL10969548 0.73 RORB (0.60) SMN1; SMN2KMT2AALDH1A1RORBCES2
SCHEMBL4963355 0.73 RAB9A (0.42) RAB9ASMN1; SMN2NPC1KDM4ETDP1
SCHEMBL9002411 0.72 TRPV1 (0.51) RAB9ASMN1; SMN2NPC1KMT2AALDH1A1
SCHEMBL12143400 0.72 KMT2A (0.55) RAB9ANPC1GRM4KMT2AALDH1A1
SCHEMBL27967469 0.72 KDM4E (0.52) SMN1; SMN2KMT2AALDH1A1RORBCES2
SCHEMBL12843987 0.72 KMT2A (0.50) RAB9ASMN1; SMN2NPC1KMT2AALDH1A1
SCHEMBL22209135 0.71 NPC1 (0.72) RAB9ASMN1; SMN2NPC1GRM4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542972-A4 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-01-23 EP disclosed
US-20070238735-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITRODMED, INC. (US) 2007-10-11 US disclosed
US-7244753-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2007-07-17 US disclosed
EP-1542972-A2 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-06-22 EP disclosed
US-20040072883-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-04-15 US disclosed
WO-2004010945-A2 CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072883-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 RAB9A 3657/4885SMN1; SMN2 2470/4885NPC1 3889/4885
US-20070238735-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGS1 RAB9A 3565/4885SMN1; SMN2 2950/4885NPC1 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.